Clinical Trial Update: Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial) [Phase 2]

View source ↗

Summary

Phase 2 ComboMATCH trial evaluating AMG 510 (sotorasib) with panitumumab for KRAS G12C-mutant solid tumors; currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Solid Tumor

Drugs mentioned

• LUMAKRAS (sotorasib)
• Vectibix (panitumumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING